Charles Bernick, MD
Neurology · Las Vegas, NVNPI 1083692743
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $30,612 of the $34,186 with a category attached, or 89.5%. 8 manufacturers reported payments, led by Eisai Inc. at 29.3% of the total. Reporting peaked in 2022 at $20,957 and has fallen 62.9% since, to $7,779 in 2025.
Across 33 payments — averaging $1035.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$10K
- Eli Lilly$9K
- Novo Nordisk$8K
- Biogen$4K
- Corium, LLC$3K
- Lilly USA, LLC$43
- plus $64 from 2 others
Across 123 payments — averaging $14,148 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$753K
- Biogen$562K
- Eli Lilly$294K
- Genentech, Inc.$79K
- Novo Nordisk AS$50K
- Avid Radiopharmaceuticals, Inc.$2K
- plus $62 from 1 others
What the payments were for
- Consulting fees$30,61290%
- Travel & lodging$3,0849%
- Food & beverage$4311%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 12 | $10,001 |
| Eli Lilly | 6 | $8,914 |
| Novo Nordisk | 6 | $7,779 |
| Biogen | 4 | $4,305 |
| Corium, LLC | 2 | $3,080 |
| Lilly USA, LLC | 1 | $43 |
| GE HealthCare | 1 | $40 |
| Boston Scientific | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,186 in reported general payments places this provider in the 85th percentile of 145 neurology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Galantamine ErGalantamine Hbr | 274 | $17,318 |
| Rivastigmine | 76 | $10,594 |
| Memantine Hcl | 64 | $2,029 |
| Donepezil Hcl | 232 | $2,027 |
| Escitalopram Oxalate | 55 | $674 |
| Bupropion Hcl | 15 | $558 |
| Mirtazapine | 49 | $324 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 17 | $181 |
| Trazodone Hcl | 26 | $145 |
| Quetiapine Fumarate | 18 | $108 |
| Citalopram HbrCitalopram Hydrobromide | 15 | $33 |
| Sertraline Hcl | 13 | $31 |
Paid to pharmacies, not to this prescriber.
Other neurology in Las Vegas
- Zoltan MariLas Vegas$629K
- Fan ZhangLas Vegas$398K
- le HuaLas Vegas$385K
- Mehdi AnsariniaLas Vegas$306K
- Carrie HershLas Vegas$209K
- Shanker DixitLas Vegas$137K
- Charles KamenLas Vegas$124K
- Toya MaloneLas Vegas$123K
- Nicole TheuvenetLas Vegas$120K
- Kevin XieLas Vegas$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.